Key result
Hypermobility spectrum disorder linked to ~5-fold higher odds of QTc prolongation vs hypermobile Ehlers-Danlos syndrome.
Why the study?
Psychoactive medications commonly used for psychiatric comorbidities in EDS and HSD raise concerns regarding potential cardiac effects.
Does psychoactive medication use affect ECG parameters differently in patients with hEDS compared to HSD?
Observational (n=109)
No
Does psychoactive medication use affect ECG parameters differently in patients with hEDS compared to HSD?
Odds Ratio: 5.33 (95% CI 1.04–27.39)
Absolute Event Rate: 26.7% vs 6.4%
p-value: p=0.045
Patients with hEDS have a higher psychiatric burden and psychoactive medication use than those with HSD, but HSD patients exhibit more frequent QTc prolongation, highlighting potential cardiovascular risks requiring monitoring.
May warrant QTc monitoring in HSD; leaves open medication effects on ECG in hypermobility disorders.
Context Ehlers-Danlos syndrome (EDS) and hypermobility spectrum disorder (HSD) are connective tissue disorders associated with musculoskeletal manifestations and significant psychiatric comorbidities. Psychoactive medications commonly utilized in these populations raise concerns regarding potential cardiac effects. Objectives This study explores associations between psychoactive medication utilization and electrocardiogram (ECG) parameters in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and HSD to provide insight into potential cardiac considerations in this population. Methods This retrospective analysis included de-identified data from patients referred for cardiac evaluation at the Long Island Heart Rhythm Center between January 2019 and June 2023. Diagnosis of EDS and HSD were made utilizing the 2017 International Classification criteria. Psychiatric diagnoses were classified per DSM-5 criteria, and psychoactive medications were categorized utilizing NIH guidelines. ECG parameters, psychiatric diagnoses, and psychoactive medication use were compared between groups. Statistical analyses included Student’s t-tests for continuous variables, chi-square or Fisher’s exact tests for categorical variables, and odds ratio (OR) calculations. Results Among 109 patients (hEDS: n=75; HSD: n=34), psychiatric diagnoses were more prevalent in hEDS patients (72 vs. 38.2 %; p=0.008), with significant differences in trauma- and stressor-related disorders (p=0.009) and ADHD (p=0.006). hEDS patients had a higher mean psychoactive medication use (1.8 vs. 1.1; p=0.019) and greater anticonvulsant use (33.3 vs. 8.8 %; p=0.008). In a subset with ECG data (n=62), QTc intervals were significantly shorter in hEDS patients (421.62 ± 22.47 ms vs. 436.73 ± 18.74 ms; p=0.022), yet within normal ranges. QTc prolongation was more frequent in HSD patients (26.7 vs. 6.4 %; OR 5.33; 95 % confidence interval (CI) [1.04–27.39]; p=0.045). Conclusions hEDS patients had a higher psychiatric burden and psychoactive medication use than HSD patients, but ECG parameters largely remained within normal limits. The increased QTc prolongation in HSD patients highlights potential cardiovascular risks, requiring further investigation. Routine cardiovascular monitoring and interdisciplinary care are recommended for hypermobile patients on psychoactive medications.
No takes yet. Share an insight, caveat, or question.
Kaushal et al. (2026) conducted an observational in Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder (n=109). Hypermobility spectrum disorder (HSD) vs. Hypermobile Ehlers-Danlos syndrome (hEDS) was evaluated on QTc prolongation (OR 5.33, 95% CI 1.04-27.39, p=0.045). Hypermobility spectrum disorder was associated with a higher frequency of QTc prolongation compared to hypermobile Ehlers-Danlos syndrome (26.7% vs 6.4%; OR 5.33; 95% CI 1.04-27.39; P=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: